Literature DB >> 8633669

Hormonal treatment for bleeding irregularities in Norplant implant users.

F Alvarez-Sanchez1, V Brache, F Thevenin, L Cochon, A Faundes.   

Abstract

OBJECTIVE: Our purpose was to evaluate whether prolonged or irregular bleeding during Norplant implant use could be alleviated with the use of oral hormonal medication. STUDY
DESIGN: One hundred fifty users of the Norplant levonorgestrel contraceptive implant with prolonged or frequent bleeding were enrolled in this prospective, randomized, comparative study and assigned to one of three treatment groups for 20 days: ethinyl estradiol 50 microg, an oral contraceptive (50 microg ethinyl estradiol and 250 microg levonogestrel), and placebo. Total days of bleeding during treatment and length of the bleeding-free interval were analyzed.
RESULTS: Women treated with the levonorgestrel-ethinyl estradiol pill bled an average of 2.6 days during treatment compared with 5.4 and 12.3 days in the ethinyl estradiol and placebo groups, respectively. Differences between both hormonal groups and placebo were significant (p <0.00001); moreover, the combined pill was more effective than ethinyl estradiol along (p <0.0001).
CONCLUSION: The combined pill proved to be an excellent palliative treatment and is a more practical approach because of availability at all clinic sites.

Entities:  

Keywords:  Americas; Caribbean; Comparative Studies; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Implants; Contraceptive Methods; Developing Countries; Diseases; Dominican Republic; Ethinyl Estradiol; Family Planning; Latin America; Levonorgestrel; Menstruation Disorders; North America; Oral Contraceptives; Oral Contraceptives, Combined; Research Methodology; Research Report; Studies; Treatment

Mesh:

Substances:

Year:  1996        PMID: 8633669     DOI: 10.1016/s0002-9378(96)70326-5

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding.

Authors:  P Warner; A Guttinger; A F Glasier; R J Lee; S Nickerson; R M Brenner; H O D Critchley
Journal:  Hum Reprod       Date:  2009-11-07       Impact factor: 6.918

Review 2.  Levonorgestrel subdermal implants. Contraception on trial.

Authors:  M L Frank; C DiMaria
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.606

Review 3.  Levonorgestrel subdermal implants. A review of contraceptive efficacy and acceptability.

Authors:  A J Coukell; J A Balfour
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

Review 4.  Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants.

Authors:  Irving Sivin
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

5.  Endometrial histology of Depomedroxyprogesterone acetate users: a pilot study.

Authors:  Andrea Ries Thurman; David E Soper
Journal:  Infect Dis Obstet Gynecol       Date:  2006

6.  Examining the efficacy, safety, and patient acceptability of the etonogestrel implantable contraceptive.

Authors:  Heather Hohmann
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.